Project description:Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with a median survival of under 15 months and no effective treatment after recurrence. A recent phase I trial of intracerebroventricular (ICV) bivalent CAR T cells in recurrent GBM showed promising responses, including tumor reduction and prolonged survival. However, relapse remains common. We performed in-depth profiling of longitudinal CSF and tumor samples from responders and non-responders to characterize immune dynamics following infusion. Our study reveals that while CAR T cells activate post-infusion across all patients, outcomes were defined by divergent remodeling of the endogenous immune landscape. Cytotoxic NK cell expansion characterized responders, whereas regulatory T cell expansion and abundant baseline immunosuppressive myeloid cells characterized non-responders. These findings indicate that host immune cells play a critical role in ICV CAR T cell therapy for GBM, suggesting that combinatorial strategies modulating the endogenous immune compartment could improve next-generation treatments.
Project description:The dataset comprises RNA-seq information of human embryonic stem cell derived pancreatic progenitors and their proliferating cells cultured in defined condition. Total RNA of each sample was isolated, labelled, and purified by standard chemistry. Sequencing libraries were prepared from 250ng of purified total mRNA using NEBNext Ultra II RNA Library Prep Kit for Illumina (NEB). Single-read RNA-sequencing was performed using the NextSeq 500 (Illumina) with 75 High Output Kit (Illumina, FC-404-2005).